Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook
TipRanksMar 19 01:35 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)
TipRanksDec 29, 2023 07:10 ET
B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1
BenzingaDec 26, 2023 06:56 ET
AlloVir Analyst Ratings
BenzingaDec 26, 2023 06:54 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)
TipRanksDec 26, 2023 06:41 ET
Hold Rating on AlloVir Following Posoleucel Program Discontinuation and Strategic Shift
TipRanksDec 22, 2023 15:05 ET
Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5
BenzingaDec 22, 2023 09:32 ET
AlloVir Analyst Ratings
BenzingaDec 22, 2023 09:27 ET
AlloVir's Positive Strides in T-Cell Therapy Development and Promising 3Q23 Financial Performance: A Buy Rating Analysis
TipRanksNov 6, 2023 00:56 ET
Piper Sandler Keeps Their Buy Rating on AlloVir (ALVR)
TipRanksNov 3, 2023 06:42 ET
AlloVir Analyst Ratings
BenzingaAug 18, 2023 06:56 ET
Bank of America Securities Initiates a Buy Rating on AlloVir (ALVR)
TipRanksAug 18, 2023 06:55 ET
AlloVir Analyst Ratings
BenzingaAug 7, 2023 10:56 ET
SVB Securities Reaffirms Their Buy Rating on AlloVir (ALVR)
TipRanksJun 28, 2023 09:45 ET
SVB Securities Sticks to Its Buy Rating for AlloVir (ALVR)
TipRanksMay 5, 2023 11:31 ET
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Moderna (MRNA) and AlloVir (ALVR)
TipRanksMay 5, 2023 07:27 ET
AlloVir (ALVR) Receives a Buy From Morgan Stanley
TipRanksApr 27, 2023 05:19 ET
SVB Securities Adjusts Price Target on AlloVir to $19 From $16, Maintains Outperform Rating
MT NewswiresApr 26, 2023 11:29 ET
SVB Securities Maintains Outperform on AlloVir, Raises Price Target to $19
BenzingaApr 26, 2023 10:36 ET
SVB Securities Reaffirms Their Buy Rating on AlloVir (ALVR)
TipRanksFeb 17, 2023 10:10 ET
No Data
No Data